Evidence map›Paper›PMID 36136146›Full record

ArticleArchivum immunologiae et therapiae experimentalis2022

Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation.

Rafael Alfaro, Santiago Llorente, Pedro Martinez, Víctor Jimenez-Coll, Helios Martínez-Banaclocha, José Antonio Galián, Carmen Botella, María Rosa Moya-Quiles, Jesús de la Peña-Moral, Alfredo Minguela and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Rafael AlfaroImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Santiago LlorenteNephrology Service, Biomedical Research Institute of Murcia (IMIB), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Pedro MartinezImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Víctor Jimenez-CollImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Helios Martínez-BanaclochaImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
José Antonio GaliánImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Carmen BotellaImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
María Rosa Moya-QuilesImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Jesús de la Peña-MoralPathology Service, Biomedical Research Institute of Murcia (IMIB), University Clinical Hospital Virgen de la Arrixaca, Murcia, Spain.
Alfredo MinguelaImmunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain.
Isabel Legaz *Department of Legal and Forensic Medicine, Biomedical Research Institute (IMIB), Regional Campus of International Excellence "Campus Mare Nostrum", Faculty of Medicine, University of Murcia, 30110, Murcia, Spain. isalegaz@um.es.ORCID http://orcid.org/0000-0002-1140-4313
Manuel Muro *Immunology Service, Biomedical Research Institute of Murcia (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain. manuel.muro@carm.es.ORCID http://orcid.org/0000-0001-9987-0994
Instituto Murciano de Investigación Biosanitaria · ESUniversidad de Murcia · ES

Funding

Instituto de Salud Carlos III P19/01194Instituto de Salud Carlos III (ISCIII) PI15/01370Instituto de Salud Carlos III (ISCIII) PI20/00050
6 · The paper itself

Abstract

BAFF system plays an essential role in B cells homeostasis and tolerance, although it has widely not been tested in transplantation with doubtful results. The main purpose was to study the BAFF soluble forms and their correlation with acute rejection (AR) and donor-specific antibodies production. Serum levels of BAFF, APRIL, and soluble forms of their receptors were analyzed in renal recipients with and without acute rejection (AR/NAR) appearance. All molecules were evaluated at pre- and post-transplantation. sTACI showed a significant correlation with BAFF and sR-BAFF levels, and sBCMA also showed a positive correlation with sAPRIL levels. A significant increase in sAPRIL levels in patients suffering AR was also found, and ROC curves analysis showed an AUC = 0.724, a concentration of 6.05 ng/ml (sensitivity: 66.7%; specificity: 73.3%), the best cutoff point for predicting AR. In the post-transplant dynamics of sAPRIL levels in the longitudinal cohort, we observed a significant decrease at 3 and 6 month post-transplantation compared to pretransplantation status. We also observed that recipients with high pre-transplant levels of sAPRIL generated antibodies earlier than those with lower sAPRIL levels, although their long-term post-transplantation was not different. Our results show that elevated serum levels of APRIL may be helpful as a biomarker for the diagnosis of AR, although the longitudinal study shows that it is not helpful as a prognostic biomarker.

Indexed as

Kidney TransplantationB-Cell Activating FactorBiomarkersGraft RejectionHumansLongitudinal StudiesTumor Necrosis Factor Ligand Superfamily Member 13B-Cell Activating FactorBiomarkersTNFSF13 protein, humanTumor Necrosis Factor Ligand Superfamily Member 13Acute rejectionBAFF system soluble formsForensic medicineKidney transplant

Identifiers

PMID36136146
OpenAlexW4296793971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.